Kim Youn-Hyun, Nijst Petra, Kiefer Kathryn, Tang W H Wilson
, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA.
Cardiovascular Division, Department of Internal Medicine, Korea University Ansan Hospital, Ansan-si, Republic of Korea.
Curr Heart Fail Rep. 2017 Apr;14(2):117-126. doi: 10.1007/s11897-017-0320-5.
The endothelial surface layer is covered with abundant proteoglycans, of which syndecans and glycosaminoglycans are major constituents.
Among the endothelial glycocalyx (eGC) constituents, syndecan-1 (sdc1) is a main component, and an elevated serum level of sdc1 may indicate the degradation of eGC. In patients with ischemic heart disease or heart failure, elevation of serum sdc1 has been associated with worsening cardiac and renal function; however, the causal relationship between degradation of eGC and clinical outcomes is unclear. Herein, we review the previous literature on eGC in cardiovascular and noncardiovascular diseases and their clinical implications.
内皮表面层覆盖着丰富的蛋白聚糖，其中多配体蛋白聚糖和糖胺聚糖是主要成分。
在内皮糖萼（eGC）成分中，多配体蛋白聚糖-1（sdc1）是主要成分，血清sdc1水平升高可能表明eGC降解。在缺血性心脏病或心力衰竭患者中，血清sdc1升高与心脏和肾功能恶化有关；然而，eGC降解与临床结局之间的因果关系尚不清楚。在此，我们回顾了先前关于eGC在心血管疾病和非心血管疾病中的文献及其临床意义。
